Literature DB >> 23824377

N-terminal pro-brain natriuretic peptide as a useful predictor of early surgery in neonates with congenital heart diseases: a prospective observational study.

Mika Makimura1, Hiroshi Koga.   

Abstract

Pediatric studies have found a correlation between the clinical heart failure score and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. However, the clinical usefulness of this marker remains unclear in neonates. At hospitals without pediatric cardiologists, neonatologists or general pediatricians must judge whether surgery is indicated and transfer patients to a specialized hospital in a timely fashion as required. Thus, we tested the hypothesis that increased NT-proBNP levels predict short-term outcomes in neonates with congenital heart diseases (CHDs) and are thus a useful tool for evaluating clinical status and guiding treatment. Subjects were term or near-term newborns (≥36 weeks' gestation) with CHDs confined to left-to-right shunt lesions. Clinical parameters and NT-proBNP levels were measured on the first 7, 14, 21, and 28 days of life (DOL). We divided patients into a surgical (n = 7) and a conservative-treatment group (n = 21), and then compared clinical variables and outcomes between the groups. In the surgical group, NT-proBNP levels had a tendency to increase during the first 14 postnatal days and were significantly greater than in the conservative-treatment group on 7 DOL [median (range), 13,983 pg/mL (4,732-26,524) vs. 1,954 pg/mL (671-10,881); p = 0.0028] and on 14 DOL [29,274 pg/mL (14,006-33,740) vs. 2,050 pg/mL (1,304-9,250); p = 0.0055]. In contrast, NT-proBNP levels tended to decrease sequentially in the conservative-treatment group. The values of additional markers, such as mean NT-proBNP level on 7 and 14 DOLs (M7-14) and NT-proBNP level on 14 DOL minus that on 7 DOL (Δ7-14), were both significantly greater in the surgical group than in the conservative-treatment group. To examine the usability of M7-14 and Δ7-14 when the difference and mean cut-off levels were set at 10,000 and 3,000 pg/mL, respectively, the sensitivity and specificity were both 100 %. In neonates who had CHDs with left-to-right shunt, analysis of the association between clinical variables and short-term outcomes showed that NT-proBNP, especially M7-14 and Δ7-14, is a useful predictor of early surgery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23824377     DOI: 10.1007/s00246-013-0744-y

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  14 in total

1.  Increased plasma levels of natriuretic peptide type B and A in children with congenital heart defects with left compared with right ventricular volume overload or pressure overload.

Authors:  Daniel Holmgren; Andreas Westerlind; Per-Arne Lundberg; Håkan Wåhlander
Journal:  Clin Physiol Funct Imaging       Date:  2005-09       Impact factor: 2.273

2.  Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children.

Authors:  L Schwachtgen; M Herrmann; T Georg; P Schwarz; N Marx; A Lindinger
Journal:  Z Kardiol       Date:  2005-06

Review 3.  Diagnostic, prognostic and therapeutic relevance of B-type natriuretic hormone and related peptides in children with congenital heart diseases.

Authors:  Massimiliano Cantinotti; Stefania Giovannini; Bruno Murzi; Aldo Clerico
Journal:  Clin Chem Lab Med       Date:  2011-02-03       Impact factor: 3.694

4.  Diagnostic accuracy of B-type natriuretic hormone for congenital heart disease in the first month of life.

Authors:  Massimiliano Cantinotti; Simona Storti; Andrea Ripoli; Luc Zyw; Maura Crocetti; Nadia Assanta; Bruno Murzi; Aldo Clerico
Journal:  Clin Chem Lab Med       Date:  2010-09       Impact factor: 3.694

5.  Biochemical markers of neonatal myocardial dysfunction.

Authors:  Cristina Maria Almeida; Manuel R G Carrapato; Fernando Pinto; Mariana Pinto; Sofia Ferreira; Denise Schmitt; Luis Marinho
Journal:  J Matern Fetal Neonatal Med       Date:  2010-09-07

6.  Analytical relationships among Biosite, Bayer, and Roche methods for BNP and NT-proBNP.

Authors:  Elizabeth Sykes; Raymond E Karcher; Janice Eisenstadt; David A Tushman; Mamtha Balasubramaniam; John Gusway; Valerie J Perason
Journal:  Am J Clin Pathol       Date:  2005-04       Impact factor: 2.493

7.  N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases.

Authors:  A Nir; B Bar-Oz; Z Perles; R Brooks; A Korach; A J J T Rein
Journal:  Acta Paediatr       Date:  2004-05       Impact factor: 2.299

Review 8.  NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies.

Authors:  Amiram Nir; Angelika Lindinger; Manfred Rauh; Benjamin Bar-Oz; Stephanie Laer; Lynn Schwachtgen; Andreas Koch; Jan Falkenberg; Thomas S Mir
Journal:  Pediatr Cardiol       Date:  2008-07-04       Impact factor: 1.655

9.  Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children.

Authors:  Manfred Rauh; Andreas Koch
Journal:  Clin Chem       Date:  2003-09       Impact factor: 8.327

10.  Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study.

Authors:  Yuk M Law; Andrew W Hoyer; Mark D Reller; Michael Silberbach
Journal:  J Am Coll Cardiol       Date:  2009-10-06       Impact factor: 24.094

View more
  2 in total

1.  Relationship Between Serum B7-H3 Levels and Prognosis of Congenital Heart Disease in Children.

Authors:  Rufang Zhang; Jin Gong; Shouqing Wang; Li Shen; Yewei Xie; Xiaobing Li
Journal:  Pediatr Cardiol       Date:  2018-10-17       Impact factor: 1.655

2.  Can NT-proBNP Levels Be an Early Biomarker of Reduced Left Ventricular Ejection Fraction in Preterm Infants?

Authors:  Ya-Lan Lin; Yi-Li Hung; Chung-Min Shen; Yung-Chuan Chen; Wu-Shiun Hsieh
Journal:  Children (Basel)       Date:  2022-07-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.